TransMedics Group Conference: CEO Outlines NOP Expansion, ENHANCE Trial Plans and Kidney Push

TransMedics Group (NASDAQ: TMDX) CEO Waleed Hassanein and CFO Gerardo Hernandez-Omana provided updates on the company's strategy, clinical trial planning, and operational initiatives during a fireside chat hosted by Oppenheimer senior medical devices analyst Suraj Kalia. Expanding TransMedics' role in the U.S. transplant ecosystem Hassanein said TransMedics began as a medical device company and emphasized the